34 results on '"Ribaudo, Heather J"'
Search Results
2. Changes in Body Mass Index with Longer-term Integrase Inhibitor Use: a Longitudinal Analysis of REPRIEVE data
3. Sex Differences in Subclinical Atherosclerosis and Systemic Immune Activation/Inflammation Among People With Human Immunodeficiency Virus in the United States
4. Cytomegalovirus Immunoglobulin G (IgG) Titer and Coronary Artery Disease in People With Human Immunodeficiency Virus (HIV)
5. Factors Associated With Systemic Immune Activation Indices in a Global Primary Cardiovascular Disease Prevention Cohort of People With Human Immunodeficiency Virus on Antiretroviral Therapy
6. Geographical Differences in the Self-Reported Functional Impairment of People With Human Immunodeficiency Virus (HIV) and Associations With Cardiometabolic Risk
7. Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus
8. COVID-19 Vaccination Rates in a Global HIV Cohort
9. Cardiovascular Risk and Health Among People With HIV Eligible for Primary Prevention: Insights From the REPRIEVE Trial
10. Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial
11. Corrigendum to: Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial
12. Leveraging a Landmark Trial of Primary Cardiovascular Disease Prevention in Human Immunodeficiency Virus: Introduction From the REPRIEVE Coprincipal Investigators
13. Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum
14. Physical Function Impairment and Frailty in Middle-Aged People Living With Human Immunodeficiency Virus in the REPRIEVE Trial Ancillary Study PREPARE
15. Erratum to: Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir
16. Racial Disparities in Virologic Failure and Tolerability During Firstline HIV Antiretroviral Therapy
17. A Randomized, Double-blinded, Placebo-controlled Trial of Sitagliptin for Reducing Inflammation and Immune Activation in Treated and Suppressed Human Immunodeficiency Virus Infection
18. Safety and Impact of Low-dose Methotrexate on Endothelial Function and Inflammation in Individuals With Treated Human Immunodeficiency Virus: AIDS Clinical Trials Group Study A5314
19. Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s
20. Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s
21. Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir
22. Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s
23. Differential Levels of Soluble Inflammatory Markers by Human Immunodeficiency Virus Controller Status and Demographics
24. Screening for UGT1A1 Genotype in Study A5257 Would Have Markedly Reduced Premature Discontinuation of Atazanavir for Hyperbilirubinemia
25. Racial Differences in Response to Antiretroviral Therapy for HIV Infection: An AIDS Clinical Trials Group (ACTG) Study Analysis
26. Clinical and Genetic Determinants of Plasma Nevirapine Exposure Following an Intrapartum Dose to Prevent Mother-to-Child HIV Transmission
27. Impact of Minority Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Resistance Genotype After Virologic Failure
28. Effect ofCYP2B6,ABCB1, andCYP3A5Polymorphisms on Efavirenz Pharmacokinetics and Treatment Response: An AIDS Clinical Trials Group Study
29. Instantaneous Inhibitory Potential Is Similar to Inhibitory Quotient at Predicting HIV‐1 Response to Antiretroviral Therapy
30. Substitution of Nevirapine because of Efavirenz Toxicity in AIDS Clinical Trials Group A5095
31. Pre‐existing Minority Drug‐Resistant HIV‐1 Variants, Adherence, and Risk of Antiretroviral Treatment Failure
32. Efavirenz‐Based Regimens in Treatment‐Naive Patients with a Range of Pretreatment HIV‐1 RNA Levels and CD4 Cell Counts
33. Preexisting Resistance to Nonnucleoside Reverse‐Transcriptase Inhibitors Predicts Virologic Failure of an Efavirenz‐Based Regimen in Treatment‐Naive HIV‐1–Infected Subjects
34. A Multilevel Analysis of Longitudinal Ordinal Data: Evaluation of the Level of Physical Performance of Women Receiving Adjuvant Therapy for Breast Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.